日韩免费视频中文在线观看-国产成人在线视频一区二区三区-天天做天天爱天天大爽-欧美α片无限看在线观看免费-日本肥熟老熟妇15p-日本中文字幕三级在线视频-成人不卡视频在线观看-日韩一区二区三区无码人妻视频-青青草绿色视频在线观看

歡迎您訪問(wèn)武漢艾美捷科技有限公司官方網(wǎng)站！
站點(diǎn)地圖 服務(wù)熱線(xiàn)：400-6800-868
  • 產(chǎn)品
  • 文章

PRODUCT CENTER

ELISA試劑盒
產(chǎn)品中心

當(dāng)前位置：首頁(yè) > 產(chǎn)品中心 > 免疫學(xué)產(chǎn)品 > ELISA試劑盒

中文名稱(chēng)

IGF-I，總（大鼠和小鼠）ELISA

英文名字
IGF-I, Total (Rat and Mouse) ELISA
供應(yīng)商
Ansh Labs
產(chǎn)品貨號(hào)
AL-137
產(chǎn)品報(bào)價(jià)
￥詢(xún)價(jià)/96wellmicrotiter
產(chǎn)品說(shuō)明書(shū)
點(diǎn)擊查看
購(gòu)買(mǎi)方式
90%產(chǎn)品中國(guó)有現(xiàn)貨庫(kù)存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線(xiàn)支付寶及網(wǎng)銀支付，或直接與我們電話(huà)聯(lián)系400-6800-868
產(chǎn)品新聞
背景資料
IGF-I, also known as somatomedin C, is a 7.6 kDa, 70 amino acid residue peptide, which mediates the actions of growth hormone (GH).1 IGF-I is synthesized as a prohormone, a polypeptide consisting of A, C, B, D, and E domains.1,2 After post-translational modification, the mature IGF-I consists of the A, C, B and D domains, and is structurally homologous to IGF-II and insulin. In vivo, IGF-I is secreted by the liver and several other tissues and is postulated to have mitogenic and metabolic actions at or near the sites of synthesis; this has been termed the paracrine role of IGF-I.1 IGF-I also appears in the peripheral circulation where it circulates primarily in a high molecular weight tertiary complex with IGF-binding protein-3 (IGFBP-3) and acid-labile subunit (ALS).2,3 A smaller proportion of IGF-I may circulate in association with other IGF-binding proteins.3 It has been estimated that <5% of plasma IGF-I circulates unbound.4 In vivo synthesis of IGF-I is stimulated by GH, and is also dependent on other factors, including adequate nutrition.1,5 IGF-I may inhibit pituitary production of GH; however, a feedback mechanism has not been completely defined.
n
nIn humans, plasma IGF-I levels are low during fetal and neonatal life, increase gradually during childhood, peak during mid-puberty, and decline gradually through adult life.1,5-7 Average plasma IGF-I levels are slightly higher in females at each age. Maternal plasma levels increase during pregnancy.1 Plasma IGF-I levels are stabilized by the IGF-binding proteins and there is negligible diurnal variation.5 Plasma IGF-I levels are low relative to age- and sex-related norms in GH deficiency5-7, malnutrition5,8 and in the syndrome of GH-receptor deficiency (Laron dwarfism).9 Abnormally low levels of plasma IGF-I have been used as a diagnostic indicator of GH deficiency, although a significant proportion of GH-deficient children may have IGF-I levels in the normal range, and normal short children may have low IGF-I levels.1,6,7 Plasma IGF-I levels may also be used to monitor the short- and long-term in vivo responses to GH treatment.5 Abnormally elevated IGF-I levels in acromegaly (GH excess) may be used as a diagnostic tool and to monitor treatment.1,5
n
nAssay of plasma IGF-I is complicated by the presence of IGF-binding proteins, which may sequester IGF-I in the reaction mixture.1 Various methods have been devised to separate the IGF and IGF-binding proteins prior to assay. Size-exclusion gel chromatography in acid is considered to be optimal1,10, but this procedure is not feasible for routine use. Acidification followed by ethanol precipitation of the IGFBP fraction1,11 gives results which are similar to acid-chromatography. SepPak C-18 cartridges are less convenient11 and give variable results and relatively low recovery.
n
nThe Ansh Labs Total Rat/Mouse IGF-I Assay uses an acidification and neutralization method to dissociate IGF-I from all the binding proteins. IGF-I levels are quantified in the extracted samples using a highly sensitive and specific enzyme-linked immunosorbent assay.
n
nReferences:
n1. Daughaday E, Rotwein P: Insulin like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocrine Rev 10:68-91, 1989.
n2. Baxter RC, Martin JL, Beniac VA: High molecular weight insulin-like growth factor binding protein complex. J Biol Chem 264:11843-11848, 1989.
n3. Rechler M: Insulin-like growth factor binding proteins. Vit Horm 47:1-114, 1993.
n4. Zapf J, Hauri C, Waldvogel M, Froesch ER: Acute metabolic effects and half-lives of intravenously administered insulin-like growth factors I and II in normal and hypophysectomized rats. J Clin Invest 77:1768-1775, 1986.
n5. Lee PDK, Rosenfeld RG: Clinical utility of insulin-like growth factor assays. Pediatrician 14:154-161, 1987.
n6. Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL: Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr 109:428-433, 1986.
n7. Lee PDK, Wilson DM, Rountree L, Hintz RL, Rosenfeld RG: Efficacy of insulin-like growth factor I levels in predicting the response to provocative growth hormone testing. Pediatr Res 27:45-51, 1990.
n8. Soliman AT, Hassan AEHI, Aref MK, Hintz RL, Rosenfeld RG, Rogol AD: Serum insulin-like growth factors I and II concentrations and growth hormone and insulin responses to arginine infusion in children with protein-calorie malnutrition before and after nutritional rehabilitation. Pediatr Res 20:1122-1130, 1986.
n9. Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Diamond FB. Jr, Rosenfeld RG: Growth hormone receptor deficiency in Ecuador: Clinical and biochemical phenotype in two populations. J Clin Endocrinol Metab 76:417-423, 1993.
n10. Powell DR, Rosenfeld RG, Baker BK, Liu F, Hintz RL: Serum somatomedin levels in adults with chronic renal failure: the importance of measuring insulin-like growth factor I (IGF-I) and IGF-II in acid-chromatographed uremic serum. J Clin Endocrinol Metab 63:1186-1192, 1986.
n11. Underwood LE, Murphy MG: Radioimmunoassay of the somatomedins. IN Patrono C (ed): Radioimmunoassay in Basic and Clinical Pharmacology (Handbook of Experimental Pharmacology vol 82) Springer-Verlag, Heidelberg, 1987, pp 561-574.
n12. HHS Publication, 5th ed., 2007. Biosafety in Microbiological and Biomedical Laboratories. Available http://www.cdc.gov/biosafety/publications/bmbl5/BMBL5
n13. DHHS (NIOSH) Publication No. 78–127, August 1976. Current Intelligence Bulletin 13 - Explosive Azide Hazard. Available http:// www.cdc.gov/niosh.
n14. Kricka L. Interferences in immunoassays – still a threat. Clin Chem 2000; 46: 1037–1038.
產(chǎn)品描述
The Total Rat/Mouse IGF-I enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of IGF-I in rat and mouse serum, plasma and other biological fluids.
產(chǎn)品特點(diǎn)
保存建議
Store at 2 to 8°C until expiration date.
其他
Ansh labs是開(kāi)發(fā)和生產(chǎn)免疫檢測(cè)試劑盒和定制生物技術(shù)檢測(cè)產(chǎn)領(lǐng)創(chuàng)者，總部位于美國(guó)休斯敦，公司產(chǎn)品遍及全球80多個(gè)國(guó)家。公司于2011年成立，核心團(tuán)隊(duì)來(lái)自于Diagnostic system laboratory，專(zhuān)注于女性健康和激素檢測(cè)領(lǐng)域近40年，擁有全球領(lǐng)先的核心技術(shù)， 以及多年經(jīng)驗(yàn)生物技術(shù)研發(fā)經(jīng)驗(yàn)的科學(xué)家團(tuán)隊(duì)，產(chǎn)品覆蓋生殖健康，高危妊娠，腫瘤，糖尿病等多個(gè)疾病領(lǐng)域，圍繞最新的免疫分析技術(shù)，多種蛋白和單克隆抗體，如AMH，BMP-15, Follistatin, GDF-9, IGF-I, IGF-II, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, Inhibin Alpha, Inhibin ?A, Inhibin ?B, MBP, PAPP-A, PAPP-A2 and Vitamin D.等幾十余種試劑產(chǎn)品，也同時(shí)涵蓋小鼠，大鼠，狗，羊，牛等靈長(zhǎng)類(lèi)多個(gè)物種的獨(dú)特的物種特異性的試劑。 Ansh labs 坐落于美國(guó)德克薩斯州，是目前世界上唯一能提供TGF-β超家族所有成員的檢測(cè)公司，也是最早專(zhuān)注激素類(lèi)產(chǎn)品研究和新型免疫檢測(cè)技術(shù)的先驅(qū)者。優(yōu)勢(shì)產(chǎn)品涉及TGF-β super family、AMH/抑制素B(human/animal)、full panel IGFs、以及最完整的胰高血糖素系列。
注意
該頁(yè)面的中文產(chǎn)品信息的翻譯，僅供參考。準(zhǔn)確的產(chǎn)品信息請(qǐng)以廠家的英文說(shuō)明書(shū)為準(zhǔn)。下單前，請(qǐng)瀏覽說(shuō)明書(shū)確認(rèn)。
在線(xiàn)留言
產(chǎn)品分類(lèi)
特色產(chǎn)品 MORE
最近促銷(xiāo) MORE
  • 高品質(zhì)保障 成熟的生產(chǎn)研發(fā)技術(shù)
  • 高性?xún)r(jià)比 價(jià)宜質(zhì)優(yōu)，性?xún)r(jià)比高
  • 高效省心 從購(gòu)買(mǎi)到使用，放心無(wú)憂(yōu)
  • 安全運(yùn)輸 完善的保護(hù)措施安全運(yùn)輸

微信掃碼在線(xiàn)客服

微信咨詢(xún)

全國(guó)免費(fèi)技術(shù)支持

400-6800-868

在線(xiàn)客服